Skip to content

Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma

Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02769806
Enrollment
16
Registered
2016-05-12
Start date
2016-05-23
Completion date
2019-06-21
Last updated
2023-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma, Glioblastoma Multiforme

Brief summary

The primary aim of this project is to Compare new msCS and standard DSC-PWI methods in GBM patients undergoing post-operative MRI for monitoring of tumor progression.

Detailed description

Investigators will compare the novel to the standard DSC-PWI methods in twenty five GBM patients to determine whether novel method improves image quality in tumor regions. We will also compare accuracy of pseudoprogression (PsP) vs. early progressive disease (ePD) determinations by the two techniques. If successful, the project will culminate in a novel imaging method sequence optimized to monitor progression and guide treatment decisions in post-operative GBM patients.

Interventions

PROCEDUREMRI

Sponsors

National Institute for Biomedical Imaging and Bioengineering (NIBIB)
CollaboratorNIH
University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 82 Years
Healthy volunteers
No

Inclusion criteria

* Histology: Glioblastoma (grade 4 astrocytoma) * Standard-of-care, post-gd T1w image changes suggestive or consistent with of progression. * Standard-of-care MRI included conventional DSC-PWI without unexpected technical difficulties. * Methylation status of tumor available in medical record. * Able to provide written informed consent.

Exclusion criteria

* Contraindications either to 3T MRI (e.g. certain metallic and electronic implants, claustrophobia) or IV gadolinium contrast (allergy, pregnancy, breast-feeding, renal insufficiency). Screening for these contraindications will be based on history only (as it is for all routine outpatient clinical MRI at UWHC). * Significant physical or mental disease which would preclude successful compliance and participation in the study or, in the opinion of the principal investigator, or co-investigator, constitute a hazard, such that enrollment in the study would not be in the patient's best interest. * Special subjects such as minors, mentally disabled persons, or prisoners.

Design outcomes

Primary

MeasureTime frameDescription
A novel high resolution DSC-PWI imaging method2 yearsA novel high resolution DSC-PWI method will be compared to the standard DSC-PWI method to determine whether novel method improves image quality in tumor regions.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026